Lung cancer is one of the most common cancers worldwide, and advances in genetic testing have revealed that not all lung cancers behave the same. Some are driven by specific gene mutations that influence how the cancer grows and how well it responds to certain treatments. One such gene is HER2 (Human Epidermal Growth Factor Receptor 2), a protein involved in cell growth and repair.
When HER2 undergoes mutations, cancer cells may proliferate more rapidly and spread more aggressively, especially in certain types of non-small cell lung cancer (NSCLC). Understanding HER2-related lung cancer helps doctors personalise treatment plans that improve survival and quality of life for patients.
HER2 is a gene that produces a protein sitting on the surface of cells. It helps regulate growth and division in healthy tissue. When a mutation occurs, HER2 may send constant signals telling the cell to multiply even when it shouldn’t.
In lung cancer, HER2 mutations:
It occurs most commonly in adenocarcinoma (a type of NSCLC).
They are found more frequently in non-smokers.
They are more common in women compared to men.
It leads to faster-growing tumours when compared to some other mutations.
Because these mutations are relatively rare, targeted therapies are designed specifically for patients with confirmed HER2-driven disease.
HER2-mutated tumours often grow more quickly and may spread earlier than other forms of lung cancer. These tumours may not respond well to traditional chemotherapy alone, which is why identifying the mutation through molecular testing is crucial.
HER2-positive lung cancer tends to:
Progress faster without targeted therapy.
Relapse sooner after chemotherapy.
Require precision medications tailored to the mutation.
Benefit from ongoing research and clinical advancements.
This is why genetic profiling of tumours has become part of modern lung cancer diagnosis.
The symptoms of HER2-driven lung cancer are similar to general lung cancer symptoms, making the mutation difficult to recognise without testing.
Common warning signs include:
Persistent cough that worsens over time
Chest discomfort or pain while breathing
Shortness of breath or wheezing
Fatigue and reduced physical activity
Coughing up blood (in advanced cases)
These symptoms should prompt medical evaluation, particularly if they are unexplained or continue to worsen.
Testing for HER2 is now a standard part of assessing advanced lung cancer. Tumour tissue or sometimes blood is analysed to identify DNA changes.
Diagnostic testing may include:
Biopsy with genetic sequencing
Liquid biopsy to detect tumour DNA in the blood
Immunohistochemistry (IHC) in some cases
Fluorescence in situ hybridisation (FISH) to assess gene amplification
Only patients with confirmed HER2 mutations are eligible for targeted therapies designed for this cancer type.
Targeted therapies that inhibit HER2 activity have shown encouraging results in reducing tumour growth and improving survival. One important example is Enhertu 100mg, which contains Trastuzumab deruxtecan, used in some cases of HER2-positive advanced lung cancer when previous treatments have failed.
These medicines:
Attach directly to HER2 receptors on cancer cells
Deliver a chemotherapy agent precisely into the tumour
Help slow cancer progression with fewer side effects on healthy tissue.
Offer an option when traditional treatments stop working.
Treatment decisions depend on how well patients tolerate therapy and how the cancer responds.
Doctors select therapies based on multiple factors:
Stage and location of cancer
Type of HER2 mutation detected
Previous treatments and side effects
Patient age and overall health
Response to earlier therapy lines
Precision oncology ensures each patient receives the therapy most likely to help them live longer with improved comfort.
Because HER2-positive lung cancer can progress quickly, a combination of treatments may be necessary.
Options may include:
Multidisciplinary care gives patients multiple strategies to fight the disease.
Even though modern lung cancer treatments are more targeted, some side effects can occur.
Supportive care may involve:
Medication to control nausea or fatigue
Pulmonary rehabilitation for breathing support
Nutritional guidance to maintain strength
Pain and stress management techniques
Frequent monitoring for heart or lung function changes
A strong support system, including family, counselling, and palliative care if needed, helps patients maintain a fulfilling life during treatment.
HER2-mutated lung cancer is an active area of clinical research. New therapies are constantly being developed to improve outcomes and reduce side effects.
Research goals include:
Identifying more precise HER2-targeted medicines
Finding ways to overcome medicine resistance
Discovering biomarkers to predict who responds best
Expanding treatment options for earlier stages of disease
As access to genetic testing increases, more patients will benefit from these breakthroughs.
HER2-positive lung cancer behaves differently from other lung cancers and can be more aggressive. However, advances in genetic testing and targeted therapies have significantly improved the way doctors diagnose and treat this condition. By tailoring treatment to the specific mutation, patients can receive more effective care with better long-term outcomes. Continuous research continues to bring new hope to individuals living with HER2-driven lung cancer.
